Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

HIV Medicine

Volumn 12, Issue 10, 2011, Pages 610-619

  McManus, H ^a   Li, Pck ^b   Nolan, D ^c   Bloch, M ^d   Kiertiburanakul, S ^e   Choi, J Y ^f   Mulhall, B ^g   Petoumenos, K ^a   Zhou, J ^a   Law, M ^a   Brew, B J ^h   Wright, E ⁱ  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c ROYAL PERTH HOSPITAL   (Australia)

^d Holdsworth House General Practice   (Australia)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Yonsei University College of Medicine   (South Korea)

^g UNIVERSITY OF SYDNEY   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

Antiretroviral therapy; Central nervous system penetration effectiveness score; Combination antiretroviral therapy; HIV; NeurocART

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; AUSTRALIA; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80054840297     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00938.x     Document Type: Article

References (26)

1. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR III. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23: 1893-1901.
2. Brew BJ. HIV, the brain, children, HAART and 'neuro-HAART': a complex mix. AIDS 2009; 23: 1909-1910.
3. Albert S, Weber CM, Todak G et al. An observed performance test of medication management ability in HIV: relation to neuropsychological status and medication adherence outcomes. AIDS Behav 1999; 3: 121-128.
4. Hinkin CH, Hardy DJ, Mason KI et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18 (Suppl 1): S19-S25.
5. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-1366.
6. Bhaskaran K, Mussini C, Antinori A et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-221.
7. Wright E, Brew B, Arayawichanont A et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 2008; 71: 50-56.
8. Gupta JD, Satishchandra P, Gopukumar K et al. Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 2007; 13: 195-202.
9. Pumpradit W, Ananworanich J, Lolak S et al. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol 2010; 16: 76-82.
10. Mayeux R, Stern Y, Tang MX et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 1993; 43: 176-182.
11. Sacktor NC, Bacellar H, Hoover DR et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol 1996; 2: 404-410.
12. Wilkie FL, Goodkin K, Eisdorfer C et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998; 10: 125-132.
13. Price RW, Yiannoutsos CT, Clifford DB et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 1999; 13: 1677-1685.
14. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52: 56-63.
15. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61: 1699-1704.
16. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
17. Letendre S, Ellis R, Deutsch R et al. Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 430].
18. The Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002; 3: 28-36.
19. Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38: 174-179.
20. Lanoy E, Guiguet M, Bentata M et al. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011; 76: 644-651.
21. Garvey L, Winston A, Sabin C, Group UCS. Does antiretroviral combination therapies with greater central nervous system (CNS) penetration prevent the development of CNS opportunistic diseases. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 427].
22. Falster K, Choi JY, Donovan B et al. AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 2009; 23: 2323-2336.
23. Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL. HIV Med 2006; 7: 383-388.
24. Baillargeon J, Borucki M, Black SA, Dunn K. Determinants of survival in HIV-positive patients. Int J STD AIDS 1999; 10: 22-27.
25. Smurzynski M, Wu KL, Letendre S et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357-365.
26. Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008; 63: 366-376.